Meeting
2019 Gastrointestinal Cancers Symposium
Impact of adjuvant hepatic arterial chemoinfusion using high-dose 5-fluorouracil with systemic gemcitabine for pancreatic cancer: A propensity score–matched analysis.
Authors
Kota Nakamura
Nara Medical University, Kashihara, Japan
Kota Nakamura , Masayuki Sho , Takahiro Akahori , Minako Nagai , Kenji Nakagawa , Tadataka Takagi , Naoya Ikeda , Toshihiro Tanaka , Hideyuki Nishiofuku , Kimihiko Kichikawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 402)
DOI
10.1200/JCO.2019.37.4_suppl.402
Abstract #
402
Poster Bd #
M2
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.
First Author: Quisette Janssen
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
First Author: Hiromichi Shirasu
Poster
2020 Gastrointestinal Cancers Symposium
Outcomes and efficacy of neoadjuvant chemoradiation versus chemotherapy in localized pancreatic cancer.
First Author: Asmita Chopra